Bellerophon Therapeutics (BLPH) Stock Forecast, Price & News

Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

Is Bellerophon Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bellerophon Therapeutics stock.
View analyst ratings for Bellerophon Therapeutics or view top-rated stocks.

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Bellerophon Therapeutics.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) released its quarterly earnings results on Wednesday, May, 11th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.04.
View Bellerophon Therapeutics' earnings history.

When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work?

Bellerophon Therapeutics shares reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for BLPH?

2 equities research analysts have issued 1 year price targets for Bellerophon Therapeutics' stock. Their forecasts range from $19.00 to $19.00. On average, they expect Bellerophon Therapeutics' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 1,943.0% from the stock's current price.
View analysts' price targets for Bellerophon Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the following people:

• Mr. Peter Fernandes M. Pharm, Principal Exec. Officer and Chief Regulatory, Safety & Quality Officer (Age 67, Pay $476.35k)
• Mr. Nicholas Laccona, Controller, Principal Financial & Accounting Officer and Sec. (Age 33)
• Dr. Parag Suresh Shah, VP of Bus. Operations (Age 45)
• Dr. Edwin L. Parsley, Acting Chief Medical Officer (Age 61)

Who are some of Bellerophon Therapeutics' key competitors?

Some companies that are related to Bellerophon Therapeutics include Ceapro (CRPOF), Vincerx (VINC), Synthetic Biologics (SYN), Celyad Oncology (CYAD), Galecto (GLTO), Acer Therapeutics (ACER), Chemomab Therapeutics (CMMB), Oragenics (OGEN), Oragenics (OGEN), Gain Therapeutics (GANX), Oncorus (ONCR), IMARA (IMRA), Adial Pharmaceuticals (ADIL), AngioSoma (SOAN) and Clever Leaves (CLVR).
View all of BLPH's competitors.

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Jane Street Group LLC (0.39%). Company insiders that own Bellerophon Therapeutics stock include New Mountain Investments Ii, L and Wassim Fares.
View institutional ownership trends for Bellerophon Therapeutics.

Which institutional investors are selling Bellerophon Therapeutics stock?

BLPH stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC.
View insider buying and selling activity for Bellerophon Therapeutics or view top insider-selling stocks.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $0.93.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics has a market capitalization of $8.88 million. The biotechnology company earns $-17.76 million in net income (profit) each year or ($1.89) on an earnings per share basis.

How many employees does Bellerophon Therapeutics have?

Bellerophon Therapeutics employs 21 workers across the globe.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is www.bellerophon.com.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at (908) 574-4770 or via email at [email protected].